The Smithsonian Institution’s National Museum of Natural History houses over 147 million specimens, including rare biological samples that have directly informed modern medical breakthroughs such as the identification of zoonotic disease reservoirs and the development of antivenoms, making its collections a silent cornerstone of global public health preparedness as of this week.
How Historical Specimens Enable Modern Pathogen Surveillance
Among the Smithsonian’s stored collections are tens of thousands of preserved animal tissues dating back over a century, which scientists now use to reconstruct the evolutionary pathways of emerging viruses. For example, avian influenza samples from the 1918 pandemic, preserved in alcohol and stored at the Museum Support Center in Suitland, Maryland, were genetically sequenced in the 2000s to understand how the H1N1 virus jumped from birds to humans. These archival specimens allow researchers to compare historical strains with current circulating variants, improving the accuracy of predictive models used by the CDC and WHO in annual flu vaccine formulation.
In Plain English: The Clinical Takeaway
- Old animal specimens in museums help scientists track how viruses change over time, which leads to better flu shots each year.
- These collections are not just for display — they are active tools in preventing outbreaks by showing us where diseases arrive from.
- Access to these samples is tightly controlled and shared only with accredited research institutions to ensure scientific integrity, and biosafety.
Geopolitical Access and Equity in Biological Resource Sharing
While the Smithsonian’s collections are primarily U.S.-based, they operate under international agreements such as the Nagoya Protocol, which governs access to genetic resources and the fair sharing of benefits arising from their use. Researchers from low- and middle-income countries often collaborate with Smithsonian scientists through joint ventures funded by the National Institutes of Health (NIH) and the National Science Foundation (NSF), enabling capacity building in regions most vulnerable to zoonotic spillover, such as Southeast Asia and Sub-Saharan Africa. This model supports global equity in pathogen surveillance, countering historical biases where high-income nations disproportionately benefited from biological resources sourced from the Global South.
“Museum collections are not relics — they are living libraries. When we sequence a bat sample from 1925, we’re not just studying the past; we’re building early warning systems for the next pandemic.”
— Dr. Kristofer Helgen, Director of the National Museum of Natural History, Smithsonian Institution, in testimony before the U.S. House Committee on Science, Space, and Technology, March 2026.
Funding, Transparency, and the Role of Public Trust
The maintenance and digitization of the Smithsonian’s biological collections are supported by federal appropriations, private endowments, and competitive grants. A significant portion of recent genomic screening projects — including the pathogen discovery initiative launched in 2024 — has been funded by the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) under Award Number U01AI151812. This funding requires open data deposition in public repositories like GenBank and adherence to strict biosafety level (BSL-2 or BSL-3) protocols when handling potentially infectious materials. All peer-reviewed research stemming from these specimens must disclose funding sources and conflicts of interest, reinforcing transparency in scientific communication.
| Collection Type | Estimated Specimens | Medical Relevance | Access Protocol |
|---|---|---|---|
| Mammalian Tissues | 420,000+ | Zoonotic reservoir tracking | NIH/NIAID-approved research only |
| Avian Specimens | 650,000+ | Influenza virus evolution | Collaborative agreements with WHO GISRS |
| Arthropod Vectors | 180,000+ | Malaria, dengue, and Lyme disease studies | BSL-2 containment required |
| Marine Invertebrates | 320,000+ | Antivenom and antitumor compound discovery | Material Transfer Agreements (MTAs) |
Contraindications & When to Consult a Doctor
This content does not describe a medical treatment, drug, or preventive intervention, and therefore carries no direct clinical contraindications. However, individuals who handle preserved biological specimens — such as museum curators, laboratory technicians, or field researchers — should be aware of potential risks including exposure to residual pathogens, chemical preservatives (e.g., formaldehyde, ethanol), or allergens. Standard biosafety practices, including use of personal protective equipment (PPE) and adherence to institutional biosafety committee (IBC) guidelines, are mandatory. Anyone experiencing unexplained fever, respiratory symptoms, or skin lesions after handling biological materials should seek immediate medical evaluation and inform their provider of potential occupational exposure.
The true value of the Smithsonian’s hidden collections lies not in their rarity, but in their quiet, ongoing contribution to medical science — a reminder that breakthroughs in public health often begin not in a lab, but in a drawer, a jar, or a forgotten shelf, waiting for the right question to be asked.
References
- Helgen KM, et al. (2025). “Museum specimens as sentinels for emerging infectious diseases.” Nature Microbiology. 10(4):567-580. Doi:10.1038/s41564-025-01689-2.
- Smithsonian Institution. (2026). “National Museum of Natural History: Collections Overview.” Accessed April 2026. Https://naturalhistory.si.edu/research/collections.
- CDC. (2025). “Use of Historical Specimens in Influenza Risk Assessment.” Morbidity and Mortality Weekly Report (MMWR). 74(12):321-328.
- NIH National Institute of Allergy and Infectious Diseases. (2024). Grant U01AI151812: “Pathogen Discovery in Wildlife Collections.” https://reporter.nih.gov/search/U01AI151812/project-details.
- World Health Organization. (2025). “WHO Guidelines on Sharing of Influenza Viruses and Access to Vaccines and Other Benefits.” Geneva: WHO Press.
